Micafungin activity against Candida albicans with diverse azole resistance phenotypes

被引:19
作者
Richards, Theresa S. [1 ,2 ]
Oliver, Brian G. [2 ]
White, Theodore C. [1 ,2 ]
机构
[1] Univ Washington, Sch Publ Hlth & Community Med, Dept Global Hlth, Seattle, WA 98195 USA
[2] Seattle Biomed Res Inst, Seattle, WA 98109 USA
关键词
echinocandins; antifungals; XTT;
D O I
10.1093/jac/dkn156
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The purpose of this study was to investigate whether mechanisms of azole resistance in Candida albicans contribute to reduced micafungin activity in vitro. Methods: MICs were determined for a collection of strains with well-characterized mechanisms of azole resistance obtained from systemic, oral and vaginal infections. This collection of strains includes those with resistance-associated phenotypes. All known molecular mechanisms of azole resistance are included in this set of isolates (alone or in combination). Micafungin activity was further investigated for a subset of isolates by agar dilution. Results: There was no correlation between any of the azole resistance mechanisms or resistance phenotypes and micafungin activity as determined by MIC, even in isolates with cross-resistance to multiple azole drugs. Overexpression of the ABC transporter CDR2 has been suggested to contribute to reduced echinocandin activity in agar dilution studies. By broth microdilution, there was no difference in MIC between the pump overexpressors and the collection as a whole. However, azole-resistant isolates from matched strains exhibited a small increase in their micafungin MICs relative to their susceptible controls. By agar dilution analysis, multiple CDR2-overexpressing strains exhibited reduced growth in the presence of micafungin relative to the laboratory strain SC5314. Conclusions: Azole resistance mechanisms do not contribute to increased micafungin MIC as determined by broth microdilution. However, within sets of matched isolates, strains overexpressing CDR2 had a slight increase in micafungin MIC. Changes in micafungin susceptibility are associated with CDR2 overexpression in agar dilution tests.
引用
收藏
页码:349 / 355
页数:7
相关论文
共 39 条
[31]   Paradoxical effect of caspofungin:: Reduced activity against Candida albicans at high drug concentrations [J].
Stevens, DA ;
Espiritu, M ;
Parmar, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3407-3411
[32]   National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin [J].
Takakura, S ;
Fujihara, N ;
Saito, T ;
Kudo, T ;
Iinuma, Y ;
Ichiyama, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) :283-289
[33]   In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi [J].
Tawara, S ;
Ikeda, F ;
Maki, K ;
Morishita, Y ;
Otomo, K ;
Teratani, N ;
Goto, T ;
Tomishima, M ;
Ohki, H ;
Yamada, A ;
Kawabata, K ;
Takasugi, H ;
Sakane, K ;
Tanaka, H ;
Matsumo, F ;
Kuwahara, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :57-62
[34]   INNOVATIVE END-POINT DETERMINATION SYSTEM FOR ANTIFUNGAL SUSCEPTIBILITY TESTING OF YEASTS [J].
TELLIER, R ;
KRAJDEN, M ;
GRIGORIEW, GA ;
CAMPBELL, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1619-1625
[35]   Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation [J].
van Burik, JAH ;
Ratanatharathorn, V ;
Stepan, DE ;
Miller, CB ;
Lipton, JH ;
Vesole, DH ;
Bunin, N ;
Wall, DA ;
Hiemenz, JW ;
Satoi, Y ;
Lee, JM ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (10) :1407-1416
[36]  
White T C, 1997, Oral Dis, V3 Suppl 1, pS102
[37]   Resistance mechanisms in clinical isolates of Candida albicans [J].
White, TC ;
Holleman, S ;
Dy, F ;
Mirels, LF ;
Stevens, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1704-1713
[38]   Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus [J].
White, TC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1482-1487
[39]   Clinical, cellular, and molecular factors that contribute to antifungal drug resistance [J].
White, TC ;
Marr, KA ;
Bowden, RA .
CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (02) :382-+